AUROBINDO

August 18, 2022

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir/ Madam,

Sub: Reason for delay in completion of acquisition of 51% stake in GLS Pharma Limited.
Ref : Email of NSE dated August 18, 2022 to submit reason for delay.

We refer to our letters dated June 18, 2022 and August 18, 2022 informing about acquisition of 51% stake in GLS Pharma Limited and completion of the transaction respectively.

In our letter dated June 18, 2022, we informed that the said acquisition is estimated to be completed before July 31, 2022, but it was completed on August 17, 2022. The reason for delay in completion of the transaction is due to delay in fulfilment of one of the conditions precedent of the acquisition and also delay in credit / transfer of the shares from one of the seller's account to the Company's account.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary